We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.
- Authors
Brixner, D. I.; McAdam-Marx, C.; Ye, X.; Boye, K. S.; Nielsen, L. L.; Wintle, M.; Misurski, D.; Fabunmi, R.
- Abstract
Aim: This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting. Methods: Eligible patients identified in the General Electric (GE) electronic medical record (EMR) research database from 1 January 2000 through 31 December 2007 were ≥18 years old with type 2 diabetes. Patients had prescription orders in the previous 395 days for metformin, a sulfonylurea, or a thiazolidinedione as monotherapy or in combination, and had at least 6 months of follow-up activity. Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months ± 45 days. Results: A total of 1709 patients were identified for study inclusion. The overall mean A1C reduction (s.e.m.) at 6 months was −0.8% (0.05) (p<0.001), weight loss was −3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was −1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and −0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078). Changes in low-density lipoprotein (LDL), triglycerides and HDL were −7.4 mg/dl (1.7) (p<0.001), −23.2 mg/dl (6.7) (p = 0.001) and −0.8 mg/dl (0.33) (p = 0.012) respectively. In a quartile analysis by weight loss, mean A1C reduction ranged from −1.1 to −0.65% in the highest to lowest weight loss quartiles respectively. Conclusions: In a real-world setting, exenatide initiation is associated with significant improvements in the measures of clinical effectiveness for type 2 diabetes. These reductions were comparable to those reported in randomized, controlled registration trials after 6 months of therapy.
- Subjects
TYPE 2 diabetes; THERAPEUTICS; MEDICAL care; MEDICAL informatics; SULFONYLUREAS
- Publication
Diabetes, Obesity & Metabolism, 2009, Vol 11, Issue 12, p1122
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/j.1463-1326.2009.01081.x